BRIVIACT (brivaracetam) is an anti-seizure medication (ASM) that helps manage symptoms associated with acute or episodic changes in people diagnosed with conditions characterized by periods of heightened symptoms, specifically epilepsy.

BRIVIACT is primarily indicated as an add-on (adjunctive) therapy for the treatment of partial-onset seizures (also known as focal seizures) with or without secondary generalization. The medication is applied across domains where additional symptomatic support is needed, particularly in clinical settings that involve acute or unstable symptom patterns.

“It helps maintain a sense of stability when symptoms are more noticeable,” is a common reflection of the patient-oriented benefits this support provides. The drug is commonly used when short-term symptomatic assistance is needed to help with symptoms that interfere with daily functioning. It supports the patient during difficult episodes by easing distress, providing support that helps ease the overall symptom burden and assists with maintaining functional stability. Its use supports general well-being during symptomatic phases and is relevant when supportive symptom management is appropriate.

Quick Fact: Relief for Symptoms Related to Heightened Physiological Activity

Regulatory References

1. European Medicines Agency (EMA) overview

Eligibility Profile: Who Can and Cannot Use Brivaracetam

The eligibility for БРИВИАК (brivaracetam) use is strictly defined by government regulatory labeling, focusing on specific population groups and health conditions.

Contraindicated Populations

Absolute contraindications prohibit use in patients with known hypersensitivity to brivaracetam, to any pyrrolidone derivative, or to any of the product's excipients. Certain metabolic conditions, such as galactose intolerance (for tablets) or hereditary fructose intolerance (for oral solution), also define non-eligibility due to formulation ingredients.

Age and Conditional Use

The medicine is generally approved for adults and certain pediatric patients; however, use is not established in infants younger than one month (FDA) or children under two years (EMA). Patients with hepatic impairment (liver disease) require a mandatory lower maximum daily dose. Use is not recommended for patients with end-stage renal disease who are undergoing dialysis. For pregnancy and lactation, use is conditional and requires a formal risk-benefit assessment, as the drug is known to be excreted into breast milk.

Interactions with other medicines and products

This section describes interaction patterns for БРИВИАК (Brivaracetam) as officially documented in government regulatory sources.

Pharmacokinetic Interactions

Co-administration with enzyme-inducing medicinal products, such as Rifampin, Phenytoin, and Carbamazepine, results in a decrease in Brivaracetam plasma concentrations. This effect is attributed to the induction of the CYP2C19 metabolic pathway. Conversely, Brivaracetam co-administration is documented to increase the plasma concentration of Phenytoin and increase the exposure of the active metabolite, Carbamazepine-epoxide.

Exposure-Altering Substances and Restrictions

Substance / Condition	Official Interaction Outcome
Rifampin (Co-administered)	Requires a mandatory dosage increase for Brivaracetam (up to double the dose) to counteract exposure reduction.
Oral Contraceptives (Ethinylestradiol/Levonorgestrel)	High doses of Brivaracetam cause a moderate decrease in the plasma levels of these hormonal components.
Hepatic Impairment	Brivaracetam exposure is significantly increased (up to 59% higher) in patients with liver cirrhosis.

Pharmacodynamic and General Restrictions

Co-administration with Ethanol (Alcohol) results in a pharmacodynamic interaction causing a larger, additive decrease in psychomotor performance and alertness. The medicine is formally contraindicated in patients with a history of hypersensitivity to Brivaracetam or other pyrrolidone derivatives.

Synaptic Activity Modulation and Neuronal Stabilization

The primary mechanism of Brivaracetam involves highly selective ligand binding to the Synaptic Vesicle Glycoprotein 2A ( SV2A) protein in central nervous system (CNS) neurons. SV2A is critical for regulating how chemical messengers are released into the synapse. By modulating this protein, the drug restricts the excessive release of excitatory neurotransmitters, which are chemical signals that contribute to neuronal overactivity. This action dampens signaling pathways associated with synchronized, high-frequency firing.

This primary mechanism is supported by a documented secondary effect: a weak, non-dominant inhibitory influence on neuronal voltage-gated sodium channels ( Na^+). This dual influence contributes to an increased threshold for electrical discharge and modulation of CNS excitability.

Furthermore, the molecule's high lipophilicity enables rapid diffusion across the Blood-Brain Barrier ( BBB), allowing for quick SV2A target occupancy and rapid engagement of the synaptic modulation process.

БРИВИАК (Brivaracetam) is administered via two methods: the oral route, which includes film-coated tablets and an oral solution, and the intravenous (IV) route, utilizing a solution for injection. Intravenous administration is reserved for situations where oral intake is temporarily impractical, and its use is limited to a maximum of four consecutive days.

---

Dosing and Frequency

The medicine is uniformly administered twice daily (BID), requiring the total daily dose to be divided into two equal amounts, typically taken approximately 12 hours apart. The standard maintenance dose range for adults is 50 mg to 200 mg per day. Treatment may be initiated at the chosen therapeutic dose without the requirement for gradual dose escalation. The administration protocol is flexible concerning meals; the dose may be taken with or without food.

---

Administration Requirements

For oral forms, tablets must be swallowed whole with liquid and must not be chewed or crushed. When using the oral solution, a calibrated measuring device is required to ensure dose accuracy. The IV solution is administered slowly over a period of two to fifteen minutes. When transitioning between the IV and oral forms, the total daily dose and frequency are maintained (1:1 conversion).

---

Population-Specific Adjustments

Specific dosage limits are defined for patient populations with impaired liver function. For all stages of hepatic impairment, the maximum daily dose is reduced to 150 mg (or 75 mg twice daily). Pediatric dosing for patients under 16 years old is based on body weight. Should treatment need to be discontinued, a gradual withdrawal process is utilized to manage the cessation of use.

Research evidence / Overview of studies for БРИВИАК

The Core Research Base: Focal Seizure Studies

The primary evidence for Brivaracetam was examined in numerous short-term randomized controlled trials (RCTs). These studies were structured to compare the outcomes observed in patient groups taking Brivaracetam against those taking a placebo, forming the basis for its regulatory review. Research primarily examined the use of Brivaracetam in patients with conditions characterized by fluctuating or episodic manifestations, specifically focal (partial-onset) seizures.

Researchers monitored key outcomes, including the percent change in focal seizure frequency over defined short periods, usually 12 weeks. They also monitored the proportion of participants whose symptoms evolved, such as the rate of patients achieving a substantial reduction in seizure frequency (the responder rate). Findings describe patterns observed in the studies when Brivaracetam was used alongside other medications for focal seizures.

Adjunctive vs. Monotherapy Evidence

The primary regulatory research focused on evaluating Brivaracetam as adjunctive therapy—meaning it was studied when added to an existing anti-seizure medication regimen. Research has also explored the use of Brivaracetam alone (monotherapy). While these studies report how symptoms evolved in the observed populations, the monotherapy evidence is limited compared to the controlled trials for adjunctive use.

Acute Use Research: Intravenous Administration for Status Epilepticus

Research has examined the use of the intravenous (IV) formulation of Brivaracetam for patients experiencing severe, prolonged seizure episodes known as status epilepticus. The research base primarily consists of uncontrolled, observational reports and retrospective case series, rather than randomized controlled trials.

The studies monitored time-based measurements, tracking how quickly seizures ceased and the proportion of patients whose acute symptoms resolved. However, the certainty remains low for this area. The total sample sizes were modest across the collected reports, and the acute setting makes it difficult to separate the measured outcomes from the influence of other rescue therapies given simultaneously in critical care.

Long-Term Studies and Follow-Up Data

Since the key placebo-controlled trials were short-term, additional open-label extension studies were conducted to gather information on long-term patterns of use, sometimes lasting several years. These studies reported on treatment retention, which is the proportion of people who continue taking the medication over time. However, because these follow-up durations were limited by the lack of a placebo comparison, long-term effects are not fully established under controlled conditions.

Common questions about БРИВИАК (FAQ)

---

Q: How long does it typically take to notice the expected effects of БРИВИАК?

Official pharmacological information indicates that the active ingredient is quickly and fully absorbed following oral administration. It also crosses the blood-brain barrier rapidly, which is consistent with a rapid engagement with its target protein in the brain.

---

Q: Do the side effects of БРИВИАК usually go away over time?

According to official product information, neurological side effects like drowsiness, dizziness, and fatigue are reported most frequently early in the course of treatment. The official product information indicates that these effects may occur at any time during treatment.

---

Q: What happens if I suddenly stop taking БРИВИАК?

Regulatory documents state that suddenly stopping any anti-seizure medicine may increase the risk of more frequent seizures, including severe, prolonged seizures known as status epilepticus. For this reason, official guidance describes a gradual withdrawal process for managing the cessation of the medicine.

---

Q: Is it possible to become dependent on БРИВИАК?

In the United States, БРИВИАК is classified as a federally controlled substance, Schedule V ( CV). This classification acknowledges a potential for misuse and the associated risk of dependence.

---

Q: How long does the effect of one dose of БРИВИАК last?

The elimination half-life (the time it takes for half of the drug to be removed from the body) is approximately 7 to 9 hours. The medicine is administered twice daily, which is consistent with maintaining consistent levels of the substance in the body.

---

Q: Is БРИВИАК considered a first-line medicine for its main use?

Official documents state the medicine is for use in the treatment of partial-onset seizures. It may be initiated either as monotherapy (used alone) or as adjunctive therapy (used with other anti-seizure medicines) in adults and certain pediatric patients.

---

Q: How does БРИВИАК compare to other medicines in the same class?

The active ingredient is a pyrrolidinone derivative chemically related to the medicine levetiracetam. Pharmacological data describe an approximately 20-fold greater affinity for the SV2A protein than levetiracetam.

---

Q: Is БРИВИАК a controlled substance?

Yes, in the United States, this medicine is designated as a federally controlled substance, Schedule V ( CV). This classification is due to a defined potential for abuse or dependence.

---

Q: Are there any common over-the-counter medicines that interact with БРИВИАК?

Co-administration with certain over-the-counter medicines or products that cause sedation (drowsiness) may result in an additive central nervous system effect. This could increase symptoms like dizziness and fatigue, according to official interaction warnings.

---

Q: Is it safe to use alcohol while taking БРИВИАК?

Official guidance recommends that patients avoid or limit alcohol consumption. Combining alcohol with the medicine may cause a greater, additive decrease in psychomotor performance and alertness due to a pharmacodynamic interaction.

---

Q: Does taking БРИВИАК require routine blood tests?

The medicine is not typically associated with the need for routine monitoring of drug blood levels. However, official information notes that low white blood cell counts (neutropenia) have been reported as an uncommon side effect.

---

Q: Is there a generic version of БРИВИАК available?

As of the current regulatory status in the United States, there is no FDA-approved generic equivalent available for this medicine.

---

Q: Is it possible for the medicine to interact with grapefruit juice?

The official product information states that no specific food interactions, including with grapefruit juice, were reported in the clinical research for this medicine.

---

Q: Is it possible to take too much БРИВИАК?

Official documents describe that an overdose is possible. Reported symptoms have included extreme sleepiness, dizziness, trouble keeping balance, blurred or double vision, slowed heartbeat, and nausea.

---

Q: Are headaches a common initial side effect when starting БРИВИАК?

Headache is listed as a reported side effect of the medicine. However, in controlled clinical studies, headache was not classified among the most frequently reported side effects, which include somnolence/drowsiness, dizziness, and fatigue.

---

Q: Can people with pre-existing mental health conditions use БРИВИАК?

Official regulatory guidance requires that a patient's history be reviewed, including any previous instances of depression, mood problems, or suicidal thoughts or behavior. This is due to the medicine's documented risk of psychiatric adverse reactions.

---

Q: Is there research on the use of БРИВИАК in pregnant individuals?

The official label notes that there is not enough data to conclusively determine the drug-associated risk of birth defects or miscarriage. Pregnancy registries are generally available to collect more long-term data about the medicine's use during pregnancy.

---

Q: What is the half-life of БРИВИАК?

The elimination half-life of the active ingredient is approximately 7 to 9 hours. This is the time it takes for half of the drug's active substance to be removed from the body.

---

Q: Is БРИВИАК used to treat only one specific condition?

No, the medicine is for use in the treatment of partial-onset seizures and is also approved as an adjunctive (add-on) treatment for other specific seizure types, including myoclonic seizures and generalized tonic-clonic seizures, in certain age groups.

How to Store and Dispose of BRIVIACT (Brivaracetam)

Official regulations require that BRIVIACT tablets, oral solution, and injection vials be stored at controlled room temperature, maintaining a range between 59 F and 86 F (15 C to 30 C). The oral solution must be kept in its tightly closed container, protected from excess heat and moisture, and must not be frozen. Due to its classification, the medicine must be stored in a safe place and kept out of the sight and reach of children.

Stability and Disposal

Product Form	Stability Limitation
Oral Solution	Discard 5 months after first opening the bottle.
Injection (Diluted)	Must not be stored for more than 4 hours at room temperature.

Unused or expired BRIVIACT must not be disposed of via wastewater or household waste. Patients are instructed to consult a pharmacist for guidance on proper disposal according to local requirements.